Drew E. Hurd
YOU?
Author Swipe
View article: Image Biomarkers for Predicting Immunotherapy Response in Advanced Melanoma 9065
Image Biomarkers for Predicting Immunotherapy Response in Advanced Melanoma 9065 Open
Description Background Immune checkpoint inhibitors (ICIs) targeting the negative regulatory checkpoints PD-1 and CTLA-4 have improved outcomes in advanced cutaneous melanoma, yet effective biomarkers to predict ICI response are lacking. O…
View article: Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma
Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma Open
Objective Immunotherapy has improved outcomes for advanced-stage melanoma, however, predictive biomarkers remain limited. We evaluated whether computed tomography (CT) features from multiple anatomical regions could predict immunotherapy r…
View article: Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption Open
Gut microbiota composition is directly associated with response to immunotherapies in cancer. The impact of diet on the gut microbiota and downstream immune responses to cancer remains unclear. In this study, we show that consumption of a …
View article: Zinc availability in the tumor microenvironment dictates anti-PD1 response in <i>CDKN2A</i> <sup>Low</sup> tumors via increased macrophage phagocytosis
Zinc availability in the tumor microenvironment dictates anti-PD1 response in <i>CDKN2A</i> <sup>Low</sup> tumors via increased macrophage phagocytosis Open
Anti-PD1 therapies are primarily thought to rely on functional T cell responses; yet tumors with limited T cell infiltration can still benefit, suggesting alternative mechanisms contribute to therapeutic efficacy. Indeed, we found that mye…
View article: Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients Open
The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota tran…
View article: 605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results
605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results Open
Background Neoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable MEL with durable relapse-free benefit, and increased circulating activated CD8+ T cells.1,2 Vidutolimod (v…